Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2022-03-11 00:00:00 ET · period of report 2022-03-10 · accession 0001209191-22-018153 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-11 | 2022-03-10 | VIR | Virgin Herbert | EVP, CSO, Research | M - OptEx | $1.53 | +9,000 | 184.4K | +5% | +$13.8K |
| D | 2022-03-11 | 2022-03-10 | VIR | Virgin Herbert | EVP, CSO, Research | M - OptEx | $0.00 | -9,000 | 210.5K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-10 | M | A | 9,000 | $1.53 | 184,407 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-10 | M | D | 9,000 | $0.00 | 210,505 | D | $1.53 · — to 2028-01-26 | 9,000 Common Stock | (F1) The option is fully vested and exercisable. |